Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Superficial Basal Cell Carcinoma

In brief

The purpose of this study is to determine the safety and tolerability of pharmaceutical compound (API 31510) topical cream topically applied to superficial basal cell carcinomas to obtain preliminary efficacy data for the treatment of superficial basal cell carcinomas by API 31510 topical cream. The study population will include one hundred and sixty (160) otherwise healthy male or female adults with one or more histologically confirmed superficial basal cell carcinoma lesions. One target lesion with an area of less than one inch will be designated for study treatment.

Key facts

Study ID: NCT00604890
Run by: BPGbio
People needed: 186
Starts: 2008-03-01
Expected to finish: 2010-01-01
Last updated by the study team: 2025-02-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Male or female adults ≥ 18 years of age
Primary, histologically confirmed sBCC with a minimum area of 0.5 cm2 and with a maximum diameter of 2.0 cm target sBCC lesion suitable for excision
Histological diagnosis made no more than 4 weeks prior to the screening visit
Histological biopsy removed 25% or less of the target lesion
No other dermatological disease in the sBCC target site or surrounding area
Willing to refrain from using non-approved lotions or creams on the target site and surrounding area during the treatment period. Willing to refrain from washing the treated area for at least 8 hours following the application of study medication
Willing to refrain from exposure to direct sunlight or ultraviolet light and to avoid the use of tanning parlors for the duration of the study
Laboratory values for the tests listed in the Study Schedule on page 2 within the reference ranges as defined by the central laboratory, or "out of range" test results that are clinically acceptable to the investigator.
Ability to follow study instructions and likely to complete all study requirements
Written informed consent obtained, including consent for tissue to be examined and stored by the central dermatopathologist
Written consent to allow photographs of the target sBCC lesion to be used as part of the study data
For females of childbearing potential, a negative pregnancy test at screening and using an acceptable form of birth control (oral/implant/injectable/transdermal contraceptives, intrauterine device, condom, diaphragm, abstinence, or a monogamous relationship with a partner who has had a vasectomy)

You may not qualify if…

Pregnant or lactating
Presence of known or suspected systemic cancer
Histological evidence of nBCC, SCC, or any other tumor in the biopsy specimen
Histological evidence of severe squamous metaplasia, infiltrative, desomoplastic or micronodular growth patterns in the biopsy specimen
History of recurrence of the target sBCC lesion
Evidence of dermatological disease or confounding skin condition in the treatment area, e.g., SCC, actinic keratosis, rosacea, psoriasis, atopic dermatitis, eczema, xeroderma pigmentosa
Concurrent disease or treatment that suppresses the immune system
Chronic medical condition that in the judgment of the investigator(s) would interfere with the performance of the study or would place the patient at undue risk
Known sensitivity to any of the ingredients in the study medication
Use of a tanning parlor or other excessive or prolonged exposure to ultraviolet light or direct sunlight during the course of the study
Treatment with systemic chemotherapeutic agents within the 6 months prior to the screening visit
Use of systemic retinoids within the 6 months prior to the screening period
Treatment with systemic immunomodulators or immunosuppressants within the 6 months prior to the screening period
Use of topical immunomodulators within 2 cm of the target BCC lesion within the 4 weeks prior to the screening period
Treatment with the following topical agents within the 4 weeks prior to the screening visit: levulanic acid, 5-fluorouracil, coricosteroids, retinoids, diclofenac, hyaluronic acid, imiquimod
Undergone a facial resurfacing procedure, i.e., chemical peel, laser resurfacing, dermabrasion, within the 6 months prior to the screening visit, if the target sBCC lesion is on the face
Treatment with liquid nitrogen, surgical excision or curettage within 2 cm of the target sBCC lesion during the 4 weeks prior to the screening visit
Elective surgery within 4 weeks prior to the screening visit, during the study, or 4 weeks after the treatment period
Evidence of current chronic alcohol or drug abuse
Current enrollment in an investigational drug or device study or participation in such a study within 4 weeks of the screening visit
In the investigator's opinion, evidence of unwillingness, or inability to follow the restrictions of the protocol and complete the study

Where it is running

Burke Pharmaceuticals — Hot Springs, Arkansas, United States
Skin Surgery Medical Group, Inc. — San Diego, California, United States
Colorado Medical Research Center — Denver, Colorado, United States
Dermatology Associates and Research — Coral Gables, Florida, United States
Gwinnett Clinical Research — Snellville, Georgia, United States
Scott D. Glazer, M.D., S.C. — Buffalo Grove, Illinois, United States
Christie Clinic — Champaign, Illinois, United States
Long Island Skin Cancer and Dermatologic Surgery, PC — Smithtown, New York, United States
Oregon Dermatology and Research Center — Portland, Oregon, United States
Dermatology Clinical Research Center of San Antonio — San Antonio, Texas, United States
Education & Research Foundation — Lynchburg, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.